Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ibotenic acid is a naturally occurring alpha-amino acid and neurotoxin found in several Amanita mushroom species (including Amanita muscaria and Amanita pantherina). It is a conformationally-restricted analogue of glutamate and acts primarily as a potent, non-selective agonist at glutamate receptors, strongly activating NMDA, group I and II metabotropic glutamate receptors, and weakly activating AMPA and kainate receptors. Through in vivo decarboxylation, ibotenic acid also serves as a prodrug for muscimol, a potent GABAA and GABAA-ρ receptor agonist. Ibotenic acid is neurotoxic and widely used in research to selectively cause excitotoxic brain lesions in animal models, particularly for studying CNS function, learning, and neurodegeneration. It induces neuronal damage by overactivating glutamate receptors, leading to calcium overload and oxidative stress.[1][4][9][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibotenic acid.